FDA says bisphenol in plastic bottles is safe

From the Associated Press

Despite ongoing safety concerns from parents, consumer groups and politicians, a chemical used in baby bottles, canned food and other items is not dangerous, federal regulators said Friday.

Scientists with the Food and Drug Administration said the trace amounts of bisphenol A that leach out of food containers are not a threat to infants or adults. The agency acknowledged that more research was needed to fully understand its effects on humans, noting: “There are always uncertainties associated with safety decisions.”

The FDA previously declared the chemical safe but agreed to revisit that opinion after a report by the National Toxicology Program said there was “some concern” about its risks to infants.


The plastic-hardening chemical, similar to the hormone estrogen, is used to seal canned food and make shatterproof bottles. It’s also used in hundreds of household items as varied as sunglasses and compact discs.

The FDA’s draft report was greeted with enthusiasm by the American Chemistry Council, which has defended the chemical’s safety.

“FDA is the government agency we rely upon to assess food-contact products. They’ve assessed this issue in great detail and their conclusion is very reassuring,” said Steve Hentges, an executive director with the council.

But environmental groups were quick to criticize the conclusions, which they said relied on industry-funded studies.

“It’s ironic FDA would choose to ignore dozens of studies funded by [the National Institutes of Health] -- this country’s best scientists -- and instead rely on flawed studies from industry,” said Pete Myers, chief scientist for Environmental Health Sciences.

Myers said the agency disregarded recent studies of bisphenol’s effects included in the National Toxicology Program’s April draft report. That group’s review of animal studies suggested that low doses of bisphenol can cause changes in behavior and the brain and that the chemical may reduce survival and birth weight in fetuses. A final version of the group’s findings is expected next month.


The FDA said those studies had “inconsistencies and inadequacies which limit the interpretations of the findings.”